Showing results (161-170 of 177) with videos related to
Sort By:
Pageof 18
Endocrinology|July 1, 1995
Further evidence for a novel receptor for amino-terminal parathyroid hormone-related protein on keratinocytes and squamous carcinoma cell linesJ J Orloff, Y Kats, P Urena, et al.Obstetrics and Gynecology|April 12, 2003
Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosisMarjorie M Luckey, Nigel Gilchrist, Henry G Bone, et al.Journal of Lipid Research|December 28, 2012
Naringenin prevents cholesterol-induced systemic inflammation, metabolic dysregulation, and atherosclerosis in Ldlr⁻/⁻ miceJulia M Assini, Erin E Mulvihill, Brian G Sutherland, et al.Journal of the American Society of Nephrology : JASN|April 24, 1999
Expression and role of parathyroid hormone-related protein in human renal proximal tubule cells during recovery from ATP depletionA García-Ocaña, S C Galbraith, S K Van Why, et al.Physiological Reviews|January 1, 1996
Defining the roles of parathyroid hormone-related protein in normal physiologyW M Philbrick, J J Wysolmerski, S Galbraith, et al.Science Advances|February 20, 2026
Engineering controlled-release steroid therapeutics: fabrication and molecular design of self-assembled microparticlesOluwaseun D Akanbi, Michael L Felder, Daniel Kupor, et al.Surgery, Gynecology & Obstetrics|July 1, 1975
Portacaval shunt as emergency procedure in unselected patients with alcoholic cirrhosisM J Orloff, A C Charters, J G Chandler, et al.The New England Journal of Medicine|April 19, 1990
Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancerW J Burtis, T G Brady, J J Orloff, et al.Patient Preference and Adherence|March 8, 2022
Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United StatesDaniel Auclair, Carol Mansfield, Mark A Fiala, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 5, 2002
Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosisR Rizzoli, S L Greenspan, G Bone, et al.Pageof 18